The annual ASCO2024 meeting was packed as always with the latest trial data and treatment advances in oncology. For those unable to visit Chicago this year, Twitter provides a glimpse into the impactful presentations and data. Here are some of the top trending abstracts and topics from this year’s meeting:
CheckMate-9DW trial
First results from the preplanned interim analysis from the phase III CheckMate-9DW trial (NCT04039607) showed nivolumab in combination with ipilimumab demonstrate a significant overall survival benefit compared to lenvatinib or sorafenib in the 1st-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
The full abstract is available here.
DESTINY-Breast06
Results from the DESTINY-Breast06 phase 3 trial found trastuzumab deruxtecan demonstrated clinically meaningful progression-free survival (PFS) improvement in patients with hormone receptor (HR)–positive, HER2-low metastatic breast cancer following endocrine therapy.
The trial results establish trastuzumab deruxtecan “as an effective new treatment option for patients with HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one line or more of endocrine-based therapy and no prior chemotherapy,” according to study presenter Giuseppe Curigliano, MD, PhD, of the University of Milan and European Institute of Oncology in Italy.
LAURA trial
Results from the phase III LAURA trial demonstrated that osimertinib significantly improved progression-free survival compared with placebo in patients with unresectable stage III EGFR-mutated non-small-cell lung cancer (NSCLC) following definitive chemoradiotherapy.
Lead author Suresh Ramalingham commented: “There are currently no approved targeted treatments specifically for unresectable stage III EGFR-mutated NSCLC. The LAURA study showed a statistically significant and clinically meaningful improvement in progression-free survival vs placebo in patients with unresectable EGFR-mutated NSCLC following definitive chemoradiotherapy. With the superior efficacy results along with the robust magnitude of benefit in the LAURA study, osimertinib provides a solution to a large unmet need for this patient population. These data suggest that osimertinib will become a new standard of care for patients with unresectable stage III EGFR-mutated NSCLC following definitive chemoradiotherapy”.
ASC4FIRST
Primary results from the phase III ASC4FIRST study demonstrated significantly superior efficacy and excellent safety and tolerability for asciminib compared to investigator-selected tyrosine kinase inhibitors in patients with newly diagnosed chronic myeloid leukemia (CML).
“[A]sciminib has the potential to become a therapy of choice for patients with newly diagnosed CML-chronic phase,” commented Timothy P. Hughes, MD, of the South Australian Health and Medical Research Institute and the University of Adelaide in Australia.
Disclosures: This article was created by the touchONCOLOGY team utilizing AI as an editorial tool (ChatGPT (GPT-4o) [Large language model]. https://chat.openai.com/chat.) The content was developed and edited by human editors. No funding was received in the publication of this article.
Don’t get to follow @touchONCOLOGY on X to hear about our latest content.
Take a look at the touchONCOLOGY conference highlights from ASCO 2024
